- Home
- EDF vs BDTX Comparison
EDF vs BDTX Comparison
Compare EDF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- BDTX
- Stock Information
- Founded
- EDF 2010
- BDTX 2014
- Country
- EDF United States
- BDTX United States
- Employees
- EDF N/A
- BDTX 54
- Industry
- EDF Investment Managers
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDF Finance
- BDTX Health Care
- Exchange
- EDF Nasdaq
- BDTX Nasdaq
- Market Cap
- EDF 148.6M
- BDTX 126.8M
- IPO Year
- EDF N/A
- BDTX 2020
- Fundamental
- Price
- EDF $4.99
- BDTX $2.24
- Analyst Decision
- EDF
- BDTX Strong Buy
- Analyst Count
- EDF 0
- BDTX 4
- Target Price
- EDF N/A
- BDTX $15.50
- AVG Volume (30 Days)
- EDF 160.6K
- BDTX 1.2M
- Earning Date
- EDF 01-01-0001
- BDTX 03-11-2025
- Dividend Yield
- EDF 13.14%
- BDTX N/A
- EPS Growth
- EDF N/A
- BDTX N/A
- EPS
- EDF N/A
- BDTX N/A
- Revenue
- EDF N/A
- BDTX N/A
- Revenue This Year
- EDF N/A
- BDTX N/A
- Revenue Next Year
- EDF N/A
- BDTX N/A
- P/E Ratio
- EDF N/A
- BDTX N/A
- Revenue Growth
- EDF N/A
- BDTX N/A
- 52 Week Low
- EDF $3.51
- BDTX $1.91
- 52 Week High
- EDF $5.50
- BDTX $7.66
- Technical
- Relative Strength Index (RSI)
- EDF 53.40
- BDTX 48.23
- Support Level
- EDF $4.96
- BDTX $2.02
- Resistance Level
- EDF $5.13
- BDTX $2.33
- Average True Range (ATR)
- EDF 0.08
- BDTX 0.17
- MACD
- EDF 0.02
- BDTX 0.03
- Stochastic Oscillator
- EDF 68.89
- BDTX 43.42
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund invests predominantly invests in fixed income securities and other instruments economically tied to emerging market countries.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.